Our goal is to develop mechanistic digital twins that simulate the response to advanced therapies and optimize their clinical application in two areas of high current relevance: radiopharmaceuticals and CAR T-cell immunotherapies. Although these therapies differ in their clinical administration, they share common challenges from a mathematical modeling perspective, such as predicting efficacy, characterizing toxicity, and understanding the emergence of resistance.